for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cara Therapeutics Inc

CARA.OQ

Latest Trade

17.31USD

Change

0.42(+2.46%)

Volume

242,624

Today's Range

16.93

 - 

17.35

52 Week Range

14.12

 - 

27.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Cara Therapeutics- On Dec. 17, CFO Mani Mohindru Gave Notice Of Resignation, Effective Dec. 20, To Accept New Opportunity With Privately Held Co

Dec 23 (Reuters) - Cara Therapeutics Inc <CARA.O>::CARA THERAPEUTICS- ON DEC 17, MANI MOHINDRU, CFO, GAVE NOTICE OF RESIGNATION, EFFECTIVE DEC 20, TO ACCEPT NEW OPPORTUNITY WITH PRIVATELY HELD CO.CARA THERAPEUTICS- RICHARD MAKARA, VP, HEAD OF ACCOUNTING & CONTROLLER, ASSUMED INTERIM CFO ROLE.

Cara Therapeutics Reports Data From Phase 2 Trial Of Korsuva

Dec 3 (Reuters) - Cara Therapeutics Inc <CARA.O>::CARA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 TRIAL OF ORAL KORSUVA™ IN CHRONIC KIDNEY DISEASE PATIENTS WITH MODERATE-TO-SEVERE PRURITUS.CARA THERAPEUTICS INC - ORAL KORSUVA WELL-TOLERATED AFTER 12 WEEKS OF TREATMENT.CARA - ORAL KORSUVA MET PRIMARY ENDPOINT WITH STATISTICALLY SIGNIFICANT REDUCTION IN MEAN WORST ITCHING INTENSITY NRS SCORES WITH 1 MG TABLET STRENGTH.

Cara Therapeutics Announces Publication Of Difelikefalin KALM-1 Phase 3 Trial Results

Nov 11 (Reuters) - Cara Therapeutics Inc <CARA.O>::CARA THERAPEUTICS ANNOUNCES PUBLICATION OF DIFELIKEFALIN (KORSUVA™ INJECTION) KALM™-1 PHASE 3 TRIAL RESULTS IN THE NEW ENGLAND JOURNAL OF MEDICINE.CARA THERAPEUTICS ANNOUNCES PUBLICATION OF DIFELIKEFALIN (KORSUVA™ INJECTION) KALM™-1 PHASE 3 TRIAL RESULTS IN THE NEW ENGLAND JOURNAL OF MEDICINE.CARA THERAPEUTICS INC - TREATMENT WITH KORSUVA INJECTION RESULTED IN STATISTICALLY SIGNIFICANT REDUCTION IN PRURITUS INTENSITY.CARA THERAPEUTICS INC - TREATMENT WITH KORSUVA RESULTED IN IMPROVEMENT IN ITCH-RELATED QUALITY OF LIFE MEASURES FOR BOTH PRIMARY, SECONDARY ENDPOINTS.

Cara Therapeutics Inc Reports Q3 Loss Per Share Of $0.74

Nov 5 (Reuters) - Cara Therapeutics Inc <CARA.O>::CARA THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.74.Q3 REVENUE $5.8 MILLION.Q3 REVENUE ESTIMATE $4.3 MILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE ESTIMATE $-0.58 -- REFINITIV IBES DATA.CARA THERAPEUTICS - AT SEPTEMBER 30, 2019, CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $249.1 MILLION VERSUS $182.8 MILLION AT DECEMBER 31, 2018.CARA THERAPEUTICS -SEES EXISTING CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE MARKETABLE SECURITIES AS OF SEPT 30, TO FUND CO INTO SECOND HALF 2021.

Cara Therapeutics Announces Completion Of Interim Statistical Assessment And Small Increase In Target Enrollment For KALM-2 Phase 3 Global Trial Of KORSUVA Injection In Hemodialysis Patients Wit

Oct 14 (Reuters) - Cara Therapeutics Inc <CARA.O>::CARA THERAPEUTICS ANNOUNCES COMPLETION OF INTERIM STATISTICAL ASSESSMENT AND SMALL INCREASE IN TARGET ENROLLMENT FOR KALM-2 PHASE 3 GLOBAL TRIAL OF KORSUVA™ INJECTION IN HEMODIALYSIS PATIENTS WITH PRURITUS.CARA THERAPEUTICS ANNOUNCES COMPLETION OF INTERIM STATISTICAL ASSESSMENT AND SMALL INCREASE IN TARGET ENROLLMENT FOR KALM-2 PHASE 3 GLOBAL TRIAL OF KORSUVA™ INJECTION IN HEMODIALYSIS PATIENTS WITH PRURITUS.CARA THERAPEUTICS INC - FULL TRIAL ENROLLMENT EXPECTED IN Q4 OF 2019.CARA THERAPEUTICS INC - PATIENT ENROLLMENT INCREASED APPROXIMATELY 20% TO MAINTAIN GREATER THAN 90% STATISTICAL POWER.CARA THERAPEUTICS - REMAIN ON TRACK TO FILE NDA FOR KORSUVA INJECTION IN SECOND HALF OF 2020.

Cara Therapeutics Enters Into Commercial License Agreement With Enteris Biopharma For Peptelligence Oral Formulation Technology

Aug 21 (Reuters) - Cara Therapeutics Inc <CARA.O>::CARA THERAPEUTICS ENTERS INTO COMMERCIAL LICENSE AGREEMENT WITH ENTERIS BIOPHARMA, INC. FOR PEPTELLIGENCE® ORAL FORMULATION TECHNOLOGY.CARA THERAPEUTICS INC - ENTERIS WILL RECEIVE AN UPFRONT PAYMENT OF $8 MILLION, INCLUDING $4 MILLION IN CASH AND $4 MILLION IN CARA COMMON STOCK.CARA THERAPEUTICS INC - ENTERIS IS ALSO ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY AND TIERED COMMERCIAL MILESTONE PAYMENTS.CARA THERAPEUTICS INC - ENTERIS IS ALSO ELIGIBLE TO RECEIVE LOW, SINGLE-DIGIT ROYALTIES BASED ON NET SALES IN LICENSED TERRITORY.CARA THERAPEUTICS INC - RETAINS RIGHT TO BUY OUT ROYALTY OBLIGATION FOR A PERIOD OF TWO YEARS UNDER PRESPECIFIED CONDITIONS..CARA THERAPEUTICS - ENTERIS GRANTED CARA NON-EXCLUSIVE LICENSE TO ITS PEPTELLIGENCE TECHNOLOGY TO DEVELOP, COMMERCIALIZE ORAL KORSUVA WORLDWIDE.

Cara Therapeutics Q2 Loss Per Share $0.58

Aug 7 (Reuters) - Cara Therapeutics Inc <CARA.O>::CARA THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.58.Q2 EARNINGS PER SHARE ESTIMATE $-0.61 -- REFINITIV IBES DATA.TOTAL REVENUE OF $5.2 MILLION AND $2.9 MILLION FOR THREE MONTHS ENDED JUNE 30, 2019 AND 2018, RESPECTIVELY.

Cara Therapeutics Announces Pricing Of $126.5 Mln Offering Of Common Stock

July 24 (Reuters) - Cara Therapeutics Inc <CARA.O>::CARA THERAPEUTICS ANNOUNCES PRICING OF $126.5 MILLION OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.50 MILLION COMMON SHARES PRICED AT $23.00PER SHARE.

Cara Therapeutics Says Commenced An Underwritten Public Offering Of 5 Mln Shares

July 24 (Reuters) - Cara Therapeutics Inc <CARA.O>::CARA THERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.CARA THERAPEUTICS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF 5 MILLION SHARES OF ITS COMMON STOCK.

Cara Therapeutics On July 8 Entered Into A Master Manufacturing Services Agreement With Patheon UK Ltd

July 12 (Reuters) - Cara Therapeutics Inc <CARA.O>::CARA THERAPEUTICS INC - ON JULY 8, CO ENTERED INTO A MASTER MANUFACTURING SERVICES AGREEMENT WITH PATHEON UK LIMITED.CARA THERAPEUTICS INC - AGREED TO ORDER FROM PATHEON AT LEAST A CERTAIN PERCENTAGE OF ITS COMMERCIAL REQUIREMENTS FOR A PRODUCT.CARA THERAPEUTICS INC - MSA HAS AN INITIAL TERM ENDING DECEMBER 31, 2023.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up